INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.400
-0.070 (-4.76%)
Apr 28, 2026, 4:00 PM EDT - Market closed

INmune Bio Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-45.93-42.08-30.01-27.3-30.34
Upgrade
Depreciation & Amortization
0.08----
Upgrade
Other Amortization
-0.080.220.240.13
Upgrade
Asset Writedown & Restructuring Costs
16.51--0.09-
Upgrade
Stock-Based Compensation
9.917.617.377.154.8
Upgrade
Other Operating Activities
-0.63----
Upgrade
Change in Accounts Payable
1.86-1.372.721.42.26
Upgrade
Change in Other Net Operating Assets
-4.392.417.72-4.27-5.35
Upgrade
Operating Cash Flow
-22.58-33.36-11.98-22.69-28.5
Upgrade
Capital Expenditures
-1.04----
Upgrade
Other Investing Activities
-----15
Upgrade
Investing Cash Flow
-1.04----15
Upgrade
Long-Term Debt Issued
----14.95
Upgrade
Total Debt Issued
----14.95
Upgrade
Long-Term Debt Repaid
--10-5--
Upgrade
Net Debt Issued (Repaid)
--10-5-14.95
Upgrade
Issuance of Common Stock
27.5528.210.780.7381.41
Upgrade
Other Financing Activities
0.07----
Upgrade
Financing Cash Flow
27.6118.21-4.230.7396.36
Upgrade
Foreign Exchange Rate Adjustments
-0.160.22-0.1-0.7-0.01
Upgrade
Net Cash Flow
3.83-14.93-16.31-22.6652.84
Upgrade
Free Cash Flow
-23.62-33.36-11.98-22.69-28.5
Upgrade
Free Cash Flow Margin
-47248.00%-238292.86%-7729.03%-6065.77%-15748.07%
Upgrade
Free Cash Flow Per Share
-0.95-1.67-0.67-1.26-1.77
Upgrade
Cash Interest Paid
-1.691.781.370.56
Upgrade
Levered Free Cash Flow
-13.03-18.45-1.4-13.27-16.53
Upgrade
Unlevered Free Cash Flow
-13.03-18.03-0.2-12.25-16.66
Upgrade
Change in Working Capital
-2.531.0410.44-2.86-3.09
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.